KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Labcorp Holdings (LH) Cash & Equivalents (2016 - 2025)

Labcorp Holdings (LH) has disclosed Cash & Equivalents for 17 consecutive years, with $532.3 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 64.95% to $532.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $532.3 million through Dec 2025, down 64.95% year-over-year, with the annual reading at $532.3 million for FY2025, 64.95% down from the prior year.
  • Cash & Equivalents hit $532.3 million in Q4 2025 for Labcorp Holdings, down from $598.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $2.0 billion in Q3 2021 to a low of $99.3 million in Q1 2024.
  • Historically, Cash & Equivalents has averaged $976.6 million across 5 years, with a median of $687.6 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: surged 484.3% in 2021 and later plummeted 86.27% in 2024.
  • Year by year, Cash & Equivalents stood at $1.5 billion in 2021, then tumbled by 78.23% to $320.6 million in 2022, then surged by 67.44% to $536.8 million in 2023, then skyrocketed by 182.92% to $1.5 billion in 2024, then crashed by 64.95% to $532.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for LH at $532.3 million in Q4 2025, $598.1 million in Q3 2025, and $647.3 million in Q2 2025.